Detalles de la búsqueda
1.
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
J Infect Dis
; 227(6): 761-772, 2023 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35904987
2.
Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
Respir Investig
; 61(2): 261-269, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36641341
3.
Investigating Tetanus, Diphtheria, Acellular Pertussis Vaccination During Pregnancy and Risk of Congenital Anomalies.
Infect Dis Ther
; 12(2): 411-423, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36520325
4.
Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy.
Vaccine
; 40(32): 4503-4512, 2022 07 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35717267
5.
Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
Vaccine
; 39(11): 1598-1608, 2021 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33612341
6.
Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial.
Vaccine
; 38(8): 2105-2114, 2020 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-31776027
7.
Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial.
Vaccine
; 38(8): 2095-2104, 2020 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-31776029
8.
Safety of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine when administered during pregnancy as part of the maternal immunization program in Brazil: a single center, observational, retrospective, cohort study.
Hum Vaccin Immunother
; 15(12): 2873-2881, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31216218
9.
Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants.
Hum Vaccin Immunother
; 15(2): 327-338, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30252603
10.
Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
Hum Vaccin Immunother
; 15(4): 809-821, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30444673
11.
Long-term antibody persistence against hepatitis B in adolescents 14-15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.
Hum Vaccin Immunother
; 15(1): 235-241, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30118633
12.
Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study.
Hum Vaccin Immunother
; 15(2): 317-326, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30431387
13.
Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
Vaccine
; 36(42): 6325-6333, 2018 10 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30197282
14.
Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer.
Expert Rev Vaccines
; 17(6): 513-524, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29920121
15.
Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Hum Vaccin Immunother
; 14(8): 1977-1986, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29630439
16.
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Vaccine
; 36(17): 2300-2306, 2018 04 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29576304
17.
Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
Vaccine
; 36(7): 986-996, 2018 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29336924
18.
Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
Hum Vaccin Immunother
; 13(7): 1505-1515, 2017 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28340322
19.
Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants.
Hum Vaccin Immunother
; 13(1): 120-127, 2017 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27629913
20.
Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants.
Hum Vaccin Immunother
; 13(3): 588-598, 2017 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27768515